Literature DB >> 18775366

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Michael G Aman1, Cristan A Farmer, Jill Hollway, L Eugene Arnold.   

Abstract

We reviewed the recent literature on medicines used to manage inattention, impulsiveness, and overactivity in children with pervasive developmental disorders (autistic disorder, pervasive developmental disorder not otherwise specified, Asperger's disorder) using computer searches of pharmacologic studies. A substantial number of reports were identified and summarized. The literature tends to be dominated by uncontrolled studies, although the number of controlled trials is growing. Findings are described for psychostimulants, noradrenergic reuptake inhibitors, antipsychotics, alpha adrenergic agonists, antidepressants, anxiolytics, cholinesterase inhibitors, N-methyl-D-aspartate receptor blockers, and antiepileptic mood stabilizers. Evidence for a positive effect is strongest for psychostimulants, noradrenergic reuptake inhibitors, antipsychotics, and alpha adrenergic agonists. Evidence for efficacy seems weakest for newer antidepressants, anxiolytics, and mood stabilizers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775366      PMCID: PMC3805750          DOI: 10.1016/j.chc.2008.06.009

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  75 in total

1.  Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design.

Authors:  S H Willemsen-Swinkels; J K Buitelaar; I A van Berckelaer-Onnes; H van Engeland
Journal:  J Autism Dev Disord       Date:  1999-04

2.  Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders.

Authors:  Antonio Y Hardan; Roger J Jou; Benjamin L Handen
Journal:  J Autism Dev Disord       Date:  2005-06

3.  Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.

Authors:  P J Santosh; G Baird; N Pityaratstian; E Tavare; P Gringras
Journal:  Child Care Health Dev       Date:  2006-09       Impact factor: 2.508

4.  A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders.

Authors:  Antonio Y Hardan; Roger J Jou; Benjamin L Handen
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

5.  Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  2005-11

6.  A crossover study of risperidone in children, adolescents and adults with mental retardation.

Authors:  Jessica A Hellings; Jennifer R Zarcone; R Matthew Reese; Maria G Valdovinos; Janet G Marquis; Kandace K Fleming; Stephen R Schroeder
Journal:  J Autism Dev Disord       Date:  2006-04

7.  Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.

Authors:  Sarah Shea; Atilla Turgay; Alan Carroll; Miklos Schulz; Herbert Orlik; Isabel Smith; Fiona Dunbar
Journal:  Pediatrics       Date:  2004-10-18       Impact factor: 7.124

8.  A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.

Authors:  Adam H Corson; John E Barkenbus; David J Posey; Kimberly A Stigler; Christopher J McDougle
Journal:  J Clin Psychiatry       Date:  2004-11       Impact factor: 4.384

9.  Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders.

Authors:  Roger J Jou; Benjamin L Handen; Antonio Y Hardan
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-04       Impact factor: 2.576

10.  Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.

Authors:  Pieter W Troost; Bertine E Lahuis; Mark-Peter Steenhuis; Cees E J Ketelaars; Jan K Buitelaar; Herman van Engeland; Lawrence Scahill; Ruud B Minderaa; Pieter J Hoekstra
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-11       Impact factor: 8.829

View more
  16 in total

1.  Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Benjamin L Handen; Michael G Aman; L Eugene Arnold; Susan L Hyman; Rameshwari V Tumuluru; Luc Lecavalier; Patricia Corbett-Dick; Xueliang Pan; Jill A Hollway; Kristin A Buchan-Page; Laura B Silverman; Nicole V Brown; Robert R Rice; Jessica Hellings; Daniel W Mruzek; Sarah McAuliffe-Bellin; Elizabeth A Hurt; Melissa M Ryan; Lynne Levato; Tristram Smith
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-09-03       Impact factor: 8.829

2.  Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.

Authors:  Marco Lamberti; Rosamaria Siracusano; Domenico Italiano; Norma Alosi; Francesca Cucinotta; Gabriella Di Rosa; Eva Germanò; Edoardo Spina; Antonella Gagliano
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

3.  Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.

Authors:  Søren Dalsgaard; Helena Skyt Nielsen; Marianne Simonsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-09       Impact factor: 2.576

Review 4.  Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder.

Authors:  Naomi Ornstein Davis; Scott H Kollins
Journal:  Neurotherapeutics       Date:  2012-07       Impact factor: 7.620

Review 5.  Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder.

Authors:  Nanda N J Rommelse; Barbara Franke; Hilde M Geurts; Catharina A Hartman; Jan K Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-02-11       Impact factor: 4.785

6.  Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Jill A Hollway; Marrisa Mendoza-Burcham; Rebecca Andridge; Michael G Aman; Benjamin Handen; L Eugene Arnold; Luc Lecavalier; Craig Williams; Laura Silverman; Tristram Smith
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-11-07       Impact factor: 2.576

7.  Focusing on Cause or Cure?: Priorities and Stakeholder Presence in Childhood Psychiatry Research.

Authors:  Lauren C Milner; Mildred K Cho
Journal:  AJOB Prim Res       Date:  2014-01-01

8.  A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders.

Authors:  Anna J Esbensen; Jan S Greenberg; Marsha Mailick Seltzer; Michael G Aman
Journal:  J Autism Dev Disord       Date:  2009-05-12

Review 9.  A review of atomoxetine effects in young people with developmental disabilities.

Authors:  Michael G Aman; Tristram Smith; L Eugene Arnold; Patricia Corbett-Dick; Rameshwari Tumuluru; Jill A Hollway; Susan L Hyman; Marissa Mendoza-Burcham; Xueliang Pan; Daniel W Mruzek; Luc Lecavalier; Lynne Levato; Laura B Silverman; Benjamin Handen
Journal:  Res Dev Disabil       Date:  2014-04-16

10.  Children with autism spectrum disorder show increased sensitivity to time-based predictability.

Authors:  Marina Kunchulia; Tamari Tatishvili; Khatuna Parkosadze; Nino Lomidze; Roland Thomaschke
Journal:  Int J Dev Disabil       Date:  2019-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.